CT HB06696

Pharmacists dispensing opioid drugs must provide patients with a personal opioid drug deactivation and disposal product at no charge, effective July 1, 2023.

Pharmacies and pharmacists may seek reimbursement from the Opioid Settlement Advisory Committee for documented expenses incurred in providing these products, with no requirement to bear expenses if settlement funds are insufficient.

The Commissioner of Consumer Protection may adopt regulations to implement the opioid drug deactivation and disposal product requirements.

Expands allowable uses of the Opioid Settlement Fund to include documented expenses incurred by pharmacies and pharmacists in providing personal opioid drug deactivation and disposal products to patients.

Maintains existing opioid settlement fund purposes including substance use disorder prevention, treatment, recovery programs, research on opioid abatement, and data tracking and reporting on drug-related harms and outcomes.